Search





Search





Markets
/
Stocks
/
nasdaq-cgen
/

Compugen Ltd

CGEN

Add to Watchlist

2.765USD

-0.265-8.75%

Market hours （ET）Quotes delayed by 15 min

258.63MMarket Cap

7.31P/E TTM



Compugen Ltd

2.765

-0.265-8.75%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Compugen Ltd

Currency: USD Updated: 2026-05-14

Key Insights

Compugen Ltd's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 112 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 6.75.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Compugen Ltd's Score

Industry at a Glance

Industry Ranking

112 / 382

Overall Ranking

228 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Compugen Ltd Highlights

StrengthsRisks

Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 117.47% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 72.76M.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Overvalued

The company’s latest PE is 8.01, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 13.75M shares, increasing 3.14% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 1.46M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.36.

Analyst Rating

Based on 5 analysts

Strong Buy

Current Rating

6.750

Target Price

+136.84%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-14

The current financial score of Compugen Ltd is 6.25, ranking 264 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 67.33M, representing a year-over-year increase of 4477.29%, while its net profit experienced a year-over-year increase of 1029.30%.

Score

Industry at a Glance

Previous score

6.25

Change



Financials

8.68

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

4.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

7.54

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.04

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Compugen Ltd's Company Valuation

Currency: USD Updated: 2026-05-14

The current valuation score of Compugen Ltd is 6.50, ranking 253 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is 8.01, which is 1038.23% below the recent high of 91.17 and 350.42% above the recent low of -20.06.

Score

Industry at a Glance

Previous score

6.50

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 112/382

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-14

The current earnings forecast score of Compugen Ltd is 9.20, ranking 9 out of 382 in the Biotechnology & Medical Research industry. The average price target is 4.00, with a high of 13.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

9.00

Change

0.2

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 5 analysts

Strong Buy

Current Rating

6.750

Target Price

+136.84%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Compugen Ltd

CGEN

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

Beigene Ltd

ONC

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-14

The current price momentum score of Compugen Ltd is 9.09, ranking 52 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.33 and the support level at 2.63, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.33

Change

1.76

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

-0.010

Neutral

RSI(14)

65.183

Neutral

STOCH(KDJ)(9,3,3)

80.873

Buy

ATR(14)

0.165

Low Volatility

CCI(14)

125.902

Buy

Williams %R

16.949

Overbought

TRIX(12,20)

0.518

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

2.896

Sell

MA10

2.817

Sell

MA20

2.824

Sell

MA50

2.496

Buy

MA100

2.148

Buy

MA200

1.859

Buy

Institutional Confidence

Currency: USD Updated: 2026-05-14

The current institutional shareholding score of Compugen Ltd is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 14.54%, representing a quarter-over-quarter decrease of 16.20%. The largest institutional shareholder is James Simons, holding a total of 1.46M shares, representing 1.54% of shares outstanding, with 1.12% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

SilverArc Capital Management, LLC

3.48M

+5.09%

Bristol Myers Squibb

1.84M

-61.32%

Renaissance Technologies LLC

Star Investors

1.46M

+3.67%

Nomura Investment Management Business Trust

1.02M

Taylor Frigon Capital Management LLC

869.23K

-9.90%

Morgan Stanley Smith Barney LLC

840.06K

-3.53%

Northern Trust Global Investments Limited

658.91K

Two Sigma Investments, LP

552.83K

+21.32%

State Street Investment Management (US)

393.80K

+3.88%

Risk Assessment

Currency: USD Updated: 2026-05-14

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Compugen Ltd. The Biotechnology & Medical Research industry's average is 3.37. The company's beta value is 2.79. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.